Nature Communications (Aug 2019)
MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancer
- Marcel A. Dammert,
- Johannes Brägelmann,
- Rachelle R. Olsen,
- Stefanie Böhm,
- Niloufar Monhasery,
- Christopher P. Whitney,
- Milind D. Chalishazar,
- Hannah L. Tumbrink,
- Matthew R. Guthrie,
- Sebastian Klein,
- Abbie S. Ireland,
- Jeremy Ryan,
- Anna Schmitt,
- Annika Marx,
- Luka Ozretić,
- Roberta Castiglione,
- Carina Lorenz,
- Ron D. Jachimowicz,
- Elmar Wolf,
- Roman K. Thomas,
- John T. Poirier,
- Reinhard Büttner,
- Triparna Sen,
- Lauren A. Byers,
- H. Christian Reinhardt,
- Anthony Letai,
- Trudy G. Oliver,
- Martin L. Sos
Affiliations
- Marcel A. Dammert
- Molecular Pathology, Institute of Pathology, University Hospital of Cologne
- Johannes Brägelmann
- Molecular Pathology, Institute of Pathology, University Hospital of Cologne
- Rachelle R. Olsen
- Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah
- Stefanie Böhm
- Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne
- Niloufar Monhasery
- Molecular Pathology, Institute of Pathology, University Hospital of Cologne
- Christopher P. Whitney
- Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah
- Milind D. Chalishazar
- Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah
- Hannah L. Tumbrink
- Molecular Pathology, Institute of Pathology, University Hospital of Cologne
- Matthew R. Guthrie
- Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah
- Sebastian Klein
- Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne
- Abbie S. Ireland
- Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah
- Jeremy Ryan
- Dana-Farber Cancer Institute, Harvard Medical School
- Anna Schmitt
- Department I of Internal Medicine, University Hospital of Cologne
- Annika Marx
- Molecular Pathology, Institute of Pathology, University Hospital of Cologne
- Luka Ozretić
- Department of Cellular Pathology, Royal Free Hospital
- Roberta Castiglione
- Else Kröner Forschungskolleg Clonal Evolution in Cancer, University Hospital Cologne
- Carina Lorenz
- Molecular Pathology, Institute of Pathology, University Hospital of Cologne
- Ron D. Jachimowicz
- Department I of Internal Medicine, University Hospital of Cologne
- Elmar Wolf
- Theodor Boveri Institute, Biocenter, University of Würzburg
- Roman K. Thomas
- Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne
- John T. Poirier
- Memorial Sloan Kettering Cancer Center
- Reinhard Büttner
- Institute of Pathology, University Hospital of Cologne
- Triparna Sen
- Department of Thoracic and Head & Neck Medical Oncology, University of Texas, MD Anderson Cancer Center
- Lauren A. Byers
- Department of Thoracic and Head & Neck Medical Oncology, University of Texas, MD Anderson Cancer Center
- H. Christian Reinhardt
- Else Kröner Forschungskolleg Clonal Evolution in Cancer, University Hospital Cologne
- Anthony Letai
- Dana-Farber Cancer Institute, Harvard Medical School
- Trudy G. Oliver
- Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah
- Martin L. Sos
- Molecular Pathology, Institute of Pathology, University Hospital of Cologne
- DOI
- https://doi.org/10.1038/s41467-019-11371-x
- Journal volume & issue
-
Vol. 10,
no. 1
pp. 1 – 11
Abstract
The expression of oncogenic MYC paralogs in small cell lung cancer is mutually exclusive. In this study, the authors show that MYC, but not MYCN or MYCL, represses BCL2, resulting in cells that are uniquely sensitive to apoptosis, and find that CHK1 and AURKA inhibitors may be useful for treating these cancers.
